Streetbeat News

Price Targets

HRZN

B. Riley Securities analyst Bryce Rowe has downgraded Horizon Tech Finance (NASDAQ:HRZN) from Neutral to Sell and set a price target of $11.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 2:27 pm

SCM

B. Riley Securities analyst Bryce Rowe has downgraded Stellus Capital Investment (NYSE:SCM) from Neutral to Sell and set a price target of $13.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 2:25 pm

FSLY

RBC Capital analyst Rishi Jaluria has upgraded Fastly (NYSE:FSLY) from Underperform to Sector Perform and increased the price target from $12 to $18.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 2:14 pm

CVX

Jefferies analyst Lloyd Byrne has upgraded Chevron (NYSE:CVX) from Hold to Buy and set a price target of $184.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 2:09 pm

CNM

Citigroup analyst Anthony Pettinari has upgraded Core & Main (NYSE:CNM) from Neutral to Buy and increased the price target from $38 to $48. This upgrade reflects a positive outlook on CNM's stock, suggesting potential growth and a higher valuation than previously estimated.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 2:07 pm

EFX

B of A Securities analyst Heather Balsky upgraded Equifax (NYSE:EFX) from Underperform to Buy and increased the price target from $164 to $300, indicating a positive outlook on the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 2:04 pm

AGL

Agilon Health (NYSE:AGL) received mixed ratings from 10 financial analysts, with a shift towards more bearish sentiment over the past three months. The average 12-month price target is now $18.3, down from $24.75, with a high estimate of $28.00 and a low of $9.00. Analysts from firms including Truist Securities, JP Morgan, JMP Securities, Deutsche Bank, Benchmark, Wells Fargo, Goldman Sachs, and RBC Capital have adjusted their ratings and price targets. Agilon Health's financial performance shows strong revenue growth but below-average profitability and efficiency metrics.

Portfolio Pulse from Benzinga Insights

January 08, 2024 | 2:01 pm

FDX

Five analysts have recently updated their ratings on FedEx (NYSE:FDX), with a mix of bullish and neutral stances. The average 12-month price target is now $304.00, down from the previous $315.25. Analysts from Melius Research, Stephens & Co., Raymond James, Barclays, and JP Morgan have adjusted their price targets, with four lowering their estimates and one announcing a new 'Buy' rating. FedEx's financials show a slight revenue decline, strong net margin, ROE, and ROA, and a healthy debt-to-equity ratio. These updates may influence investors' perceptions of FedEx's stock performance in the short term.

Portfolio Pulse from Benzinga Insights

January 08, 2024 | 2:00 pm

ENOV

Analysts have provided mixed reviews on Enovis (NYSE:ENOV) over the past three months, with 6 bullish ratings, including recent updates to price targets and ratings. The average 12-month price target for Enovis is now $70.17, up from $66.75, with a high estimate of $75.00 and a low of $62.00. Enovis is a medical technology company with segments in Prevention & Recovery and Reconstructive surgery, showing strong revenue growth and financial performance despite a lower market capitalization compared to industry peers.

Portfolio Pulse from Benzinga Insights

January 08, 2024 | 2:00 pm

AXP

Analysts have provided mixed evaluations for American Express (NYSE:AXP) over the last three months, with a total of 14 ratings ranging from bullish to bearish. The average 12-month price target for AXP is $179.36, with a high of $205.00 and a low of $151.00, marking a slight decrease from the previous average of $180.88. Recent actions by analysts include various rating adjustments and price target changes. American Express, a global financial services company, has shown strong financial performance with a revenue growth rate of 13.57%, a net margin of 15.76%, an ROE of 8.95%, an ROA of 0.98%, and a debt-to-equity ratio of 1.76.

Portfolio Pulse from Benzinga Insights

January 08, 2024 | 2:00 pm